DD155989A5 - Verfahren zur herstellung von 6(r)-[2-(8'-acyloxy-2'-methyl-6'-methyl-(oder wasserstoff)-polyhydronaphtyl-1')-aethyl]-4-(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-onen und von derivaten dieser verbindungen - Google Patents

Verfahren zur herstellung von 6(r)-[2-(8'-acyloxy-2'-methyl-6'-methyl-(oder wasserstoff)-polyhydronaphtyl-1')-aethyl]-4-(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-onen und von derivaten dieser verbindungen Download PDF

Info

Publication number
DD155989A5
DD155989A5 DD81227405A DD22740581A DD155989A5 DD 155989 A5 DD155989 A5 DD 155989A5 DD 81227405 A DD81227405 A DD 81227405A DD 22740581 A DD22740581 A DD 22740581A DD 155989 A5 DD155989 A5 DD 155989A5
Authority
DD
German Democratic Republic
Prior art keywords
alkyl
compounds
item
formula
compound
Prior art date
Application number
DD81227405A
Other languages
German (de)
English (en)
Inventor
Alvin K Willard
Robert L Smith
William F Hoffman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27494171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD155989(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/175,232 external-priority patent/US4293496A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DD155989A5 publication Critical patent/DD155989A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
DD81227405A 1980-02-04 1981-02-03 Verfahren zur herstellung von 6(r)-[2-(8'-acyloxy-2'-methyl-6'-methyl-(oder wasserstoff)-polyhydronaphtyl-1')-aethyl]-4-(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-onen und von derivaten dieser verbindungen DD155989A5 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11804980A 1980-02-04 1980-02-04
US11805180A 1980-02-04 1980-02-04
US17546080A 1980-08-05 1980-08-05
US06/175,232 US4293496A (en) 1980-02-04 1980-08-05 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones

Publications (1)

Publication Number Publication Date
DD155989A5 true DD155989A5 (de) 1982-07-21

Family

ID=27494171

Family Applications (1)

Application Number Title Priority Date Filing Date
DD81227405A DD155989A5 (de) 1980-02-04 1981-02-03 Verfahren zur herstellung von 6(r)-[2-(8'-acyloxy-2'-methyl-6'-methyl-(oder wasserstoff)-polyhydronaphtyl-1')-aethyl]-4-(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-onen und von derivaten dieser verbindungen

Country Status (22)

Country Link
EP (1) EP0033538B1 (enExample)
AU (1) AU548996B2 (enExample)
CA (1) CA1199322A (enExample)
CY (1) CY1404A (enExample)
DD (1) DD155989A5 (enExample)
DE (1) DE3173042D1 (enExample)
DK (1) DK157292C (enExample)
ES (1) ES8609296A1 (enExample)
FI (1) FI78082C (enExample)
GR (1) GR74798B (enExample)
HK (1) HK16488A (enExample)
IE (1) IE51478B1 (enExample)
IL (1) IL62044A (enExample)
MA (1) MA19054A1 (enExample)
MY (1) MY8700745A (enExample)
NL (1) NL930009I2 (enExample)
NO (2) NO154229C (enExample)
NZ (1) NZ196172A (enExample)
PT (1) PT72441B (enExample)
RO (1) RO82367B (enExample)
SG (1) SG61087G (enExample)
YU (1) YU28181A (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692381B2 (ja) * 1980-03-31 1994-11-16 三共株式会社 Ｍｂ−５３０ａ誘導体
US4343814A (en) * 1980-11-17 1982-08-10 Merck & Co., Inc. Hypocholesterolemic fermentation products
US4432996A (en) * 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
EP0094443A1 (en) * 1982-05-17 1983-11-23 Merck & Co. Inc. 6(R)-(2-(8(S) (2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S))ethyl)-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, process for preparing and pharmaceutical composition containing the same
US4503072A (en) * 1982-12-22 1985-03-05 Merck & Co., Inc. Antihypercholesterolemic compounds
ES8609193A1 (es) * 1983-01-24 1986-07-16 Sandoz Ag Procedimiento para preparar analogos de mevalonolactona y derivados de los mismos
DE3480923D1 (de) * 1983-10-11 1990-02-08 Merck & Co Inc Verfahren zur c-methylierung von 2-methylbutyraten.
EP0137444B1 (en) * 1983-10-11 1990-01-31 Merck & Co. Inc. Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-Decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
US4668699A (en) * 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
GB8915280D0 (en) * 1989-07-04 1989-08-23 British Bio Technology Compounds
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
ES2131037T3 (es) * 1995-12-06 2001-12-16 Balkanpharma Razgrad Ad Procedimiento de preparacion de lovastatina.
CA2185961A1 (en) 1996-09-19 1998-03-20 K.S. Keshava Murthy Process for producing simvastatin
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
SI9800057A (sl) * 1998-02-26 1999-08-31 Krka, Tovarna Zdravil, D.D. Postopek za pripravo simvastatina in njegovih derivatov
CA2240983A1 (en) 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
BR9916484A (pt) 1998-12-23 2002-01-22 Searle Llc Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares
CZ20012341A3 (cs) 1998-12-23 2001-12-12 G. D. Searle Llc Corparate Patent Department Kombinace inhibitorů transferoního proteinu cholesterylesterů a derivátů kyseliny fibrové pro kardiovaskulární indikace
HK1045114A1 (zh) 1998-12-23 2002-11-15 G‧D‧瑟尔有限公司 适用於心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
PT1140188E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores do transporte de acidos biliares do ileo e de inibidores da proteina de transferencia de esteres de colesterilo para doencas cardiovasculares.
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
EP1340510A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
AU2001240115A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
AU2001284469A1 (en) 2000-09-07 2002-03-22 Kaneka Corporation Methods for crystallization of hydroxycarboxylic acids
CA2464685A1 (en) 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
SI21187A (sl) 2002-03-26 2003-10-31 Krka, Tovarna Zdravil D.D., Novo Mesto Postopek za pripravo 4-oksitetrahidropiran-2-onov
KR20040092790A (ko) * 2003-04-29 2004-11-04 씨제이 주식회사 심바스타틴 중간체 제조방법
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
RS53084B (sr) 2006-07-05 2014-06-30 Takeda Gmbh Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4, kao što je roflumilast, roflumilast-n-oksid za lečenje inflamatornih plućnih obolenja
WO2009013764A2 (en) * 2007-07-24 2009-01-29 Jubilant Organosys Limited Process for producing 6(r)-[2-(8'(s)-2 ',2 '-dimethylbutyryloxy-2'(s),6'(r)-dimethyl-1,2,6,7', 8',8a'(r)- hexahydronaphthyl-l'(s))ethyl]-4(r)-hydroxy-3,4,5,6- tetrahydro-2h-pyran-2-one
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
ES2343049B1 (es) 2008-10-15 2011-06-10 Neuron Biopharma, S.A. Biosintesis de derivados de monacolina j.
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2241561A1 (en) * 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
ES2380473B1 (es) * 2010-10-13 2013-02-19 Neuron Biopharma, S.A. Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico.
KR20140108705A (ko) 2011-12-29 2014-09-12 트러스티즈 오브 터프츠 칼리지 재생 및 염증 반응을 제어하기 위한 생체물질의 기능화
RU2015101113A (ru) 2012-06-15 2016-08-10 Дженентек, Инк. Антитела против pcsk9, составы, дозы и способы применения

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049495A (en) 1974-06-07 1977-09-20 Sankyo Company Limited Physiologically active substances and fermentative process for producing the same
JPS5612114B2 (enExample) * 1974-06-07 1981-03-18
DE2748825C2 (de) 1976-11-02 1986-11-27 Sankyo Co., Ltd., Tokio/Tokyo Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
JPS6026094B2 (ja) 1978-07-04 1985-06-21 三共株式会社 テトラヒドロｍｌ↓−２３６ｂおよびその誘導体並びにそれを有効成分とする高脂血症治療剤
JPS5925599B2 (ja) * 1979-02-20 1984-06-19 三共株式会社 新生理活性物質モナコリンｋおよびその製造法
GR69216B (enExample) * 1979-06-15 1982-05-07 Merck & Co Inc
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
PT72394B (en) 1980-02-04 1982-09-06 Merck & Co Inc Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics

Also Published As

Publication number Publication date
MY8700745A (en) 1987-12-31
NO1994001I1 (no) 1994-07-01
ES499079A0 (es) 1985-10-16
NO154229C (no) 1986-08-13
CA1199322A (en) 1986-01-14
PT72441A (pt) 1981-03-01
DK157292C (da) 1990-05-07
HK16488A (en) 1988-03-11
FI810287L (fi) 1981-08-05
NO154229B (no) 1986-05-05
EP0033538A3 (en) 1982-02-24
IE51478B1 (en) 1987-01-07
GR74798B (enExample) 1984-07-12
DE3173042D1 (en) 1986-01-09
SG61087G (en) 1987-10-23
ES8609296A1 (es) 1985-10-16
IE810204L (en) 1981-08-04
NO810358L (no) 1981-08-05
NL930009I2 (nl) 1993-09-16
RO82367A (ro) 1984-02-21
EP0033538A2 (en) 1981-08-12
EP0033538B1 (en) 1985-11-27
IL62044A (en) 1987-03-31
CY1404A (en) 1988-04-22
FI78082B (fi) 1989-02-28
NZ196172A (en) 1985-01-31
DK157292B (da) 1989-12-04
MA19054A1 (fr) 1981-10-01
RO82367B (ro) 1984-02-28
DK46181A (da) 1981-08-05
IL62044A0 (en) 1981-03-31
PT72441B (pt) 1984-08-01
FI78082C (fi) 1989-06-12
AU548996B2 (en) 1986-01-09
YU28181A (en) 1983-10-31
NL930009I1 (nl) 1993-04-01
AU6657381A (en) 1981-08-13

Similar Documents

Publication Publication Date Title
DD155989A5 (de) Verfahren zur herstellung von 6(r)-[2-(8'-acyloxy-2'-methyl-6'-methyl-(oder wasserstoff)-polyhydronaphtyl-1')-aethyl]-4-(r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-onen und von derivaten dieser verbindungen
US4444784A (en) Antihypercholesterolemic compounds
US4450171A (en) Antihypercholesterolemic compounds
US4293496A (en) 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones
US4351844A (en) Hypocholesterolemic hydrogenation products and process of preparation
US3983140A (en) Physiologically active substances
US4282155A (en) Antihypercholesterolemic compounds
DD157344A5 (de) Verfahren zur herstellung von polyhydro-3,7-dimethyl-8-2-(tetrahydro-4-hydroxy-6-oxo-2h-pyran-2-yl)-aethyl-1-napthtylenyl-2-methylbutanoaten und deren entsprechenden saeuren
JPS6366306B2 (enExample)
CH655090A5 (de) Hexahydronaphthalinderivate und ihre herstellung.
US4503072A (en) Antihypercholesterolemic compounds
JPS641476B2 (enExample)
EP0033537B1 (en) Hydrogenation products of mevinolin and dihydromevinolin, a process for preparing the same and an antihypercholesterolemic pharmaceutical composition containing the same
EP0068038A1 (en) (+)-(4R,6S)-(E)-6-(2-(4'-fluoro-3,3',5-trimethyl-(1,1'-biphenyl)-2-yl)ethenyl)-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one, a process for preparing and a pharmaceutical composition containing the same
DE3112566A1 (de) Monacolin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
DE3621024C2 (de) 11beta-Phenylestradiene, deren Herstellung und diese enthaltende pharmazeutische Präparate
CH678855A5 (enExample)
US4472426A (en) Antihypercholesterolemic compounds
FR2518546A1 (fr) Dihydro- et tetrahydromonacolines l, leur procede de preparation et leur application en therapeutique
DE69023097T2 (de) Mevalonsäure-Derivate.
EP0469480A2 (de) Verfahren zur stereoselektiven Herstellung von 5-substituierten delta-Lactonen und deren Verwendung
EP0143403A2 (de) Verfahren zur Herstellung von Indanyl-Derivaten und deren Verwendung
KR850000669B1 (ko) 항 과콜레스테린 혈증성 화합물의 제법
CA1171424A (en) ( )-(4r, 6s) - (e)-6-[2-(4'fluro-3,3', 5-trimethyl- [l,l'-biphenyl]-2-yl)ethenyl]-3,4,5,6- tetrahydro-4-hydroxy-2h-pyran-2-one
DE2722911A1 (de) Glykoside von 2,6-bis-(hydroxyphenyl)- 3,7-dioxabicyclo eckige klammer auf 3.3.0 eckige klammer zu octan, verfahren zu deren herstellung und diese enthaltende arzneimittel